| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2010137351 |
| Title |
Aryl Substituted Carboxamide Derivatives As Calcium or Sodium Channel Blockers. |
| Abstract |
The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blockers such as NaV1.3 and NaV1.7, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved. |
| Applicant(s) |
Raqualia Pharma Inc |
| Representative Drug(s) |
D0M8WO |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D0OP5F
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2013122897 |
| Title |
Dihydrobenzoxazine and Tetrahydroquinoxaline Sodium Channel Inhibitors. |
| Abstract |
The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention. |
| Applicant(s) |
Amgen Inc |
| Patent ID |
WO2011058766 |
| Title |
Aryl Carboxamide Derivatives As Ttx-S Blockers. |
| Abstract |
The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar1 is phenyl; Ar2 is aryl; n is 1-4; X is -O-, -S-, -SO- or ...O2-, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of such disorders and diseases as pain in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases as pain in which voltage gated sodium channels are involved. |
| Applicant(s) |
Raqualia Pharma Inc |
| Representative Drug(s) |
D03WBS |
Drug Info
|
N.A. |
[1] |
